The IFN-α2b + all-trans retinoic acid (ATRA) regimen, IFN-α2b + paclitaxel + concomitant radiation regimen and IFN-α2b + cisplatin + 5-FU + leucovorin + concomitant radiation regimen were proven to be effective in advanced renal cell carcinoma, advanced ovarian cancer and advanced nasopharyngeal cancer, respectively [211–215]. This evidence concerns the gene IFNA2 and renal cell carcinoma.